DexCom, Inc. (DXCM) Insider Terrance H. Gregg Sells 10,000 Shares
DexCom, Inc. (NASDAQ:DXCM) insider Terrance H. Gregg sold 10,000 shares of the firm’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $56.86, for a total value of $568,600.00. Following the sale, the insider now directly owns 484,559 shares in the company, valued at approximately $27,552,024.74. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
DexCom, Inc. (NASDAQ:DXCM) traded down $0.04 during mid-day trading on Thursday, hitting $56.28. The stock had a trading volume of 1,232,609 shares, compared to its average volume of 2,046,800. DexCom, Inc. has a 1 year low of $42.62 and a 1 year high of $86.32. The company has a debt-to-equity ratio of 0.84, a quick ratio of 5.50 and a current ratio of 5.86. The company has a market cap of $4,890.00, a price-to-earnings ratio of -98.74 and a beta of 0.31.
DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Wednesday, November 1st. The medical device company reported ($0.04) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.11. DexCom had a negative return on equity of 20.44% and a negative net margin of 7.21%. equities analysts forecast that DexCom, Inc. will post -0.64 earnings per share for the current year.
Several brokerages recently issued reports on DXCM. BMO Capital Markets reaffirmed an “outperform” rating and set a $62.00 target price (down from $90.00) on shares of DexCom in a research report on Thursday, September 28th. Raymond James Financial lowered DexCom from an “outperform” rating to a “mkt perform” rating in a research report on Friday, September 29th. Canaccord Genuity reaffirmed a “buy” rating and set a $69.00 target price (down from $90.00) on shares of DexCom in a research report on Thursday, September 28th. TheStreet lowered DexCom from a “c-” rating to a “d+” rating in a research report on Wednesday, October 25th. Finally, Stephens reaffirmed a “buy” rating and set a $70.00 target price (down from $83.00) on shares of DexCom in a research report on Thursday, September 28th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and fourteen have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $68.50.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.